Quick Answer
Semnur Pharmaceuticals, Inc. reported R&D Expense of $2.55 million for fiscal year 2025.
Semnur Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.55M | +49.0% |
| 2024 | $1.71M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.14M | +390.6% | +390.6% |
| September 30, 2024 | $233.0K | — | — |
- Semnur Pharmaceuticals, Inc. showed an increase of +49.0% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, Semnur Pharmaceuticals, Inc.’s r&d expense has grown by 49.0% (from $1.71 million to $2.55 million).
- The most recent figure is from Semnur Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: